News for BELLUS Health Inc. (0A4U.L)

Ms. Colacot brings over 25 years of quality leadership experience across the biopharmaceutical and medical device industries NEW YORK, Jan. 21, 2025 (GLOBE

**media[442518]**

-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily...

AI sentiment analysis for trading uses AI to read market sentiment from news and social media. Traders can predict market movements and plan their trades

The Global Transthyretin Amyloidosis Treatment Market Size was Valued at USD 5.52 Billion in 2023 and the Worldwide Transthyretin Amyloidosis Treatment...

GuruFocus Article or News written by GuruFocus Research and the topic is about:

Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as patents for some of the industry's blockbuster drugs are on the expiration cliff.

BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Composite Index...

BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Completion Index...

BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Capped Composite Index...

Sign up for our FREE Newsletter and get: The Beginner’s Handbook For…

Toward the end of trading Monday, the Dow traded down 0.67% to 35,728.62 while the NASDAQ fell 0.92% to 15,487.41. The S&P also fell, dropping...

Toward the end of trading Monday, the Dow traded down 0.67% to 35,728.62 while the NASDAQ fell 0.92% to 15,487.41. The S&P also fell, dropping 0.58% to ...